Venrock Healthcare Capital Partners III, L.P. 13D and 13G filings for Viridian Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-02-14 6:05 pm Unchanged | 2024-12-31 | 13G | Viridian Therapeutics, Inc. VRDN | Venrock Healthcare Capital Partners III, L.P. | 3,575,309 4.500% | 0 (Unchanged) | Filing |
| 2024-11-14 5:52 pm Sale | 2024-09-30 | 13G | Viridian Therapeutics, Inc. VRDN | Venrock Healthcare Capital Partners III, L.P. | 3,575,309 5.500% | -1,980,259 (-35.64%) | Filing |
| 2024-02-14 8:28 pm Purchase | 2023-12-31 | 13G | Viridian Therapeutics, Inc. VRDN | Venrock Healthcare Capital Partners III, L.P. | 5,555,568 9.990% | 1,324,947 (+31.32%) | Filing |
| 2023-02-14 4:30 pm Purchase | 2022-12-31 | 13G | Viridian Therapeutics, Inc. VRDN | Venrock Healthcare Capital Partners III, L.P. | 4,230,621 9.990% | 2,025,353 (+91.84%) | Filing |
| 2022-02-14 4:19 pm Purchase | 2021-12-31 | 13G | Viridian Therapeutics, Inc. VRDN | Venrock Healthcare Capital Partners III, L.P. | 2,205,268 9.990% | 262,213 (+13.49%) | Filing |
| 2021-10-14 4:05 pm Purchase | 2021-10-04 | 13G | Viridian Therapeutics, Inc. VRDN | Venrock Healthcare Capital Partners III, L.P. | 1,943,055 9.990% | 1,943,055 (New Position) | Filing |